Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1310098
Reference Type
Journal Article
Title
High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol
Author(s)
Brice, P; Simon, D; Bouabdallah, R; Bélanger, C; Haïoun, C; Thieblemont, C; Tilly, H; Harousseau, JL; Doyen, C; Martin, C; Brousse, N; Solal-Céligny, PH; Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Year
2000
Is Peer Reviewed?
Yes
Journal
Annals of Oncology
ISSN:
0923-7534
EISSN:
1569-8041
Volume
11
Issue
12
Page Numbers
1585-1590
Language
English
PMID
11205467
Abstract
BACKGROUND:
Among the 566 patients with follicular lymphomas (FL) included in the GELF 86 prospective trials from October 1986 to September 1995, 372 with progressive/relapsing disease were analyzed retrospectively to identify prognostic factors at first relapse.
PATIENTS AND METHODS:
For progressive FL, patients received mono- (22%) or polychemotherapy (78%) followed by high-dose therapy (HDT) with ASCT for 83 patients (22%). The median time to progression from initial treatment was 23 months (range 3-102 months) and 24% of documented patients (52 of 217) had histological transformation (HT). Salvage therapy produced an overall response in 64% of patients and the five-year survival from progression was 42%.
RESULTS:
For patients who underwent HDT with ASCT compared to standard treatment, five-year freedom from second failure was at 42% vs. 16% (P = 0.0001) and five-year survival was 58% vs. 38% (P = 0.0005), respectively. The benefit of HDT and ASCT remained if we consider only patients less than 65 years (five-year survival at 60% vs. 40%; P = 0.001). Multivariate analysis of parameters significant according to univariate analysis found that no ASCT at first progression, age at relapse > 50 years, progression on-therapy were adversely significant on survival.
CONCLUSIONS:
HDTwith ASCT compared to standard treatment prolonged remission and survival after first progression of FL patients.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity